HSBC India Export Opportunities Fund
The scheme seeks to generate long-term capital growth from an actively managed portfolio of equity and equity related securities of companies engaged in or expected to benefit from export of goods or services. There is no assurance that the objective of the scheme will be realised and the scheme does not assure or guarantee any returns.
Growthvine rating: 3/5 — ranked #83 of 179 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹11.79 (as of 2026-08-21) |
|---|
| AUM | ₹1,201 Cr |
|---|
| Expense ratio | 1.86% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Abhishek Gupta |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -20.91% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 107.0% of Nifty 500's upside and 73.9% of its downside.
Market cap allocation
| Large cap | 42.7% |
|---|
| Mid cap | 12.1% |
|---|
| Small cap | 45.3% |
|---|
Concentration
| Top 5 holdings | 22.5% |
|---|
| Top 10 holdings | 37.4% |
|---|
| Total holdings | 47 |
|---|
Top holdings
- Avalon Technologies Limited — 6.4%
- Pearl Global Industries Limited — 4.7%
- Hindalco Industries Ltd. — 4.1%
- Reliance Industries Ltd — 3.8%
- Divis Laboratories Ltd. — 3.5%
- GARWARE HI-TECH FILMS LIMITED — 3.5%
- Larsen & Toubro Limited — 3.3%
- TVS Motor Company Ltd. — 2.8%
- Wockhardt Ltd — 2.8%
- Torrent Pharmaceuticals Ltd. — 2.5%
Top sectors
- Pharma & Biotech — 14.5%
- Electricals — 11.8%
- Automobile — 9.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 16.8% | Q1 (Top) | #11 of 167 |
| 2025 | 0.9% | Q3 | #91 of 132 |